Barr’s Duramed President Ben-Maimon Plans Departure
This article was originally published in The Tan Sheet
Executive Summary
Barr will start searching for a successor for Carole Ben-Maimon, MD, President and COO of its Duramed Research subsidiary, as soon as possible, the firm announced Dec. 19
You may also be interested in...
New Barr exec
G. Frederick Wilkinson will join Barr in the new position of President and COO of Duramed Pharmaceuticals effective in March, the firm announces Jan. 10. Wilkinson is not a replacement for Duramed Research President Carole Ben-Maimon, who announced her resignation in December (1"The Tan Sheet" Jan, 2, 2006, p. 9). Nonetheless, Wilkinson will manage all aspects of the firm's proprietary products subsidiary, which encompasses the emergency contraceptive Plan B. Growth of the proprietary products business over the last five years to $400 mil. in sales makes it "appropriate to have a management structure dedicated to these operations," according to Barr Chairman and COO Bruce Downey. Wilkinson previously served as CEO of Columbia Labs...
New Barr exec
G. Frederick Wilkinson will join Barr in the new position of President and COO of Duramed Pharmaceuticals effective in March, the firm announces Jan. 10. Wilkinson is not a replacement for Duramed Research President Carole Ben-Maimon, who announced her resignation in December (1"The Tan Sheet" Jan, 2, 2006, p. 9). Nonetheless, Wilkinson will manage all aspects of the firm's proprietary products subsidiary, which encompasses the emergency contraceptive Plan B. Growth of the proprietary products business over the last five years to $400 mil. in sales makes it "appropriate to have a management structure dedicated to these operations," according to Barr Chairman and COO Bruce Downey. Wilkinson previously served as CEO of Columbia Labs...
New Barr exec
G. Frederick Wilkinson will join Barr in the new position of President and COO of Duramed Pharmaceuticals effective in March, the firm announces Jan. 10. Wilkinson is not a replacement for Duramed Research President Carole Ben-Maimon, who announced her resignation in December (1"The Tan Sheet" Jan, 2, 2006, p. 9). Nonetheless, Wilkinson will manage all aspects of the firm's proprietary products subsidiary, which encompasses the emergency contraceptive Plan B. Growth of the proprietary products business over the last five years to $400 mil. in sales makes it "appropriate to have a management structure dedicated to these operations," according to Barr Chairman and COO Bruce Downey. Wilkinson previously served as CEO of Columbia Labs...